1. , , , et al. Urinary dysfunction in multiple sclerosis. J Clin Neurosci 2009; 16:1321–4.
2. , , , Neurologic abnormalities in multiple sclerosis. J Urol 1982; 128:541–5.
3. , Abnormalities of detrusor and sphincter function in multiple sclerosis. Br J Urol 1976; 43:193–8.
4. Urinary bladder dysfunction in multiple sclerosis. Neurology 1978; 29:52–8.
5. , , , et al. Relationship between lower urinary tract abnormalities and disease-related parameters in multiple sclerosis. J Urol 1995; 154:169–73.
6. , , , Urinary, faecal and sexual dysfunction in patients with multiple sclerosis. J Neurol 1999; 246:1027–32.
7. , Sexual and urological dysfunction in multiple sclerosis: better understanding and improved therapies. Curr Opin Neurol 2002; 15:271–8.
8. ., , , et al. The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines. Mult Scler 2007; 13:915–28.
9. , , , et al. Prevalence of bladder, bowel and sexual problems among multiple sclerosis patients two to five years after diagnosis. Mult Scler 2007; 13:106–12.
10. , , Localization in Clinical Neurology. Philadelphia: Lippincott, Williams and Wilkins, 2007.
11. Basic neuroanatomy and neurophysiology of the urethrovesical function with special reference to extended hysterectomy. CME J Gynecologic Oncol 2002; 7:32–5.
12. , , , , Relationship of bladder dysfunction to lesion site in multiple sclerosis. J Urol 2003; 169:1384–7.
13. Topographic distribution of plaques in the spinal cord in multiple sclerosis. Arch Neurol Psychol 1950; 63:382–414.
14. The cervical cord in multiple sclerosis. Neuropathol Appl Neurobiol 1978; 4:151–62.
15. , The centrifugal pathway for micturition within the spinal cord. J Neurol 1958; 21:177–89.
16. , Detrusor external sphincter dyssynergia in men with multiple sclerosis: an ominous urologic condition. J Urol 1984; 131:91–4.
17. The neurophysiology of micturition: a clinical study of 550 patients. J Urol 1982; 127:958–63.
18. , , Vesicourethral dysfunction in multiple sclerosis. J Urol 1979; 122:342–7.
19. , Neurologic aspects of detrusor-sphincter dyssynergia, with reference to the guarding reflex. J Urol 1982; 127:953–7.
20. , Urodynamic findings and long term outcome management of patients with multiple sclerosis-induced lower urinary tract dysfunction. J Urol 1984; 132:713–15.
21. , , Urinary symptoms and the neurological features of bladder dysfunction in multiple sclerosis. J Neurol Neurosurg Psych 1993; 56:245–50.
22. , Lower urinary tract dysfunction in multiple sclerosis. Urology 1992; 39:67–70.
23. , , , et al. Relationship between neurologic and urologic status in patients with multiple sclerosis. J Urol 1984; 139:499–502.
24. , , The urodynamic characteristics of multiple sclerosis. Br J Urol 1981; 53:672–5.
25. , Urodynamics and multiple sclerosis. Urol Clin North Am 1996; 23:475–81.
26. , , , et al. Modulation of the spinobulbospinal micturition reflex in cats. Am J Physiol 1992; 262:478–84.
27. , , Properties of the descending limb of the spinal-bulbospinal reflex pathway in the cat. Brain Res 1991; 556:6–12.
28. , Bladder and urethral innervation in multiple sclerosis. Br J Urol 1976; 48:239–43.
29. , , , et al. Neurophysiology of the striated sphincter muscle in multiple sclerosis. Br J Urol 1991; 68:81–8.
30. , , Pharmacotherapy for neurogenic detrusor overactivity. Am J Phys Med Rehabil 2006; 85:536–45.
31. , , , et al. Evidence for early lower urinary tract dysfunction in multiple sclerosis. J Urol 1991; 145:1219–24.
32. , , Neuroimaging in multiple sclerosis. Neurol Clin 1995; 13:147–71.
33. , Magnetic resonance imaging in the differential diagnosis and monitoring of the treatment of multiple sclerosis. Curr Opin Neurol 1996; 9:178–86.
34. , , , et al. The correlation of urodynamic findings with cranial magnetic resonance imaging findings in multiple sclerosis. J Urol 1998; 159:972–6.
35. , , , et al. Structural correlates of neurourologic abnormalities in multiple sclerosis. Eur Neurol 1992; 32:228–30.
36. , , Clinical correlation in 64 patients with multiple sclerosis. J Neurol 1986; 43:1145–8.
37. , , , et al. Correlation of magnetic resonance imaging with neuropsychological testing in multiple sclerosis. Neurology 1989; 39:161–6.
38. , , , Relation between objective and subjective measures of bladder dysfunction in multiple sclerosis. Neurology 2004; 63:1716–18.
39. , , Role of limited evaluation and aggressive medical management in multiple sclerosis: a review of 113 patients. J Urol 1994; 151:946–50.
40. , Treatment of multi-resistant urinary infections in patients with multiple sclerosis. Pharmacol Weekly 1987; 9(Suppl):76–7.
41. , , , et al. Health related quality of life measures for women with urinary incontinence: the Incontinence Impact Questionnaire and the Urogential Distress Inventory. Qual Life Res 1994; 3:291–306.
42. , SEAPI QMM incontinence classification system. Neurourol Urodyn 1992; 11:187–99.
43. , , , Qualiveen, a urinary-disorder specific instrument: 0.5 corresponds to the minimal important difference. J Clin Epid 2008; 61:505–10.
44. , , , et al. A UK consensus on the management of the bladder in multiple sclerosis. J Neurol Neurosurg Psychiatry 2009; 80:470–7.
45. Bladder dysfunction in multiple sclerosis: causes and treatment. Int Mult Scler J 1996; 1:431–40.
46. , Laboratory diagnosis of urinary tract infections in adult patients. Med Microbiol 2004; 38:1150–7.
47. , , , Transportation delay and the microbiological quality of clinical specimens. Am J Clin Pathol 1975; 64:689–93.
48. , Laboratory diagnosis of urinary tract infections in adult patients. Med Microbiol 2004; 38:1150–8.
49. Laboratory in the diagnosis and management of urinary tract infections. Med Clin N Am 1991; 75:313–25.
50. , Management of upper urinary tract complications of multiple sclerosis by means of urinary diversion to an ileal conduit. J Urol 1965; 93:169.
51. , , , Functional urinary outlet obstruction causing urosepsis in a male multiple sclerosis patient. J Emerg Med 1992; 10:281–4.
52. , , , et al. Voiding dysfunction due to multiple sclerosis: a large scale retrospective analysis. Int Braz J Urol 2009; 35:326–33.
53. , , Analysis of the upper urinary tract function in multiple sclerosis patients. Acta Neurol Scand 2008; 118:115–19.
54. , , Urodynamic studies in female patients with multiple sclerosis. Am J Obstet Gynecol 1981; 139:273–6.
55. , , Cystometric and sphincter abnormalities in multiple sclerosis. Neurology 1973; 23:1131–9.
56. , , Vesical dysfunction in multiple sclerosis. Urology 1985; 128:541–5.
57. , Neurourodynamic evaluation of voiding dysfunction in multiple sclerosis. Acta Neurol Scand 1984; 69:402–11.
58. , Review of neurogenic bladder in multiple sclerosis. Urology 1979; 14:33–5.
59. , , Urodynamic patterns in multiple sclerosis. J Urol 1979; 122:648–50.
60. , , Intravesical oxybutynin for refractory detrusor overactivity. Presented at the Annual Meeting of the Urodynamics Society, San Antonio, TX, 1993.
61. Neurogenic bladder in the women with multiple sclerosis. J Urol 1978; 120:555–6.
62. , , , Carbon dioxide cystometry and postural changes in patients with multiple sclerosis. Arch Phys Med Rehabil 1988; 69:923–7.
63. , , Multiple sclerosis and the urologist. J Urol 1999; 161:743–57.
64. , , Women with voiding dysfunction secondary to bladder outlet dyssynergia in the setting of multiple sclerosis do not demonstrate significantly elevated intravesical pressures. Urology 2007; 69:893–897.
65. , Multiple sclerosis and diabetic neurogenic bladder. In , , eds. Atlas of Urodynamics, 1st edn. Philadelphia PA: Lippincott Williams & Wilkins, 1996, 187–9.
66. , , , Bladder, bowel and sexual dysfunction in patients with multiple sclerosis: a cohort study. Scand J Urol Nephrol 1996; 179(Suppl):61–6.
67. , , Clean intermittent self-catheterization in 172 adults. Br J Urol 1990; 65:20–3.
68. Treatment of detrusor hyperreflexia in multiple sclerosis: a double blind cross over clinical trial comparing methantheline bromide (Banthine), flavoxate chloride (Uripas) and meladrazine tartarate (Lisidonil). Urol Int 1977; 32:209–17.
69. , , , et al. Detrusor hyperreflexia in multiple sclerosis. Alleviation by combination of imipramine and propantheline, a clinico-laboratory study. Eur Neurol 1979; 18:33–7.
70. , Management of vesical dysfunction in multiple sclerosis: the role of drug therapy. Urology 1980; 16:444–7.
71. , , , Dysfunction of the detrusor and urethra in multiple sclerosis: the role of drug therapy. Can J Surg 1982; 25:259–62.
72. , Urologic dysfunction in patients with multiple sclerosis. Semin Neurol 1988; 8:159–65.
73. , , , et al. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology 2003; 62:237–42.
74. , , , et al. Randomized, double blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004; 172:1919–24.
75. , , , et al. A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder. BJU Int 2005; 95:993–1001.
76. , , , et al. Efficacy of trospium chloride in patients with detrusor instability: a placebo controlled, randomized, double blind, multicenter clinical trial. BJU Int 2000; 85:659–64.
77. , , , Detrusor-external sphincter dyssynergia. J Urol 1981; 125:542–4.
78. , Electrodiagnosis of striated urethral sphincter dysfunction. J Urol 1978; 122:361–5.
79. , , A critical approach of the methods of measuring leak point pressures in women with stress incontinence. Obstet Gynecol 1995; 86:349–52.
80. , , Bladder dysfunction in multiple sclerosis. Br Med J 1965; 1:1265–9.
81. , , , Anticholinergics for urinary symptoms in multiple sclerosis. Cochrane Database Syst Rev 2009, Issue 1. Art. No.: CD004193. DOI: 10.1002/14651858.CD004193.pub2
82. , , , , The impact of the overactive bladder syndrome on sexual function: a preliminary report from the Multicenter Assessment of Transdermal Therapy in Overactive Bladder with Oxybutynin trial. Am J Obstet Gynecol 2006; 195:1730–5.
83. , , , et al. Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects. Mayo Clin Proc 2003; 78:696–702.
84. Transdermal oxybutynin: a new treatment for overactive bladder. Expert Opin Pharmacol 2003; 4:2315–24.
85. Pharmacologic approaches to the management of bladder dysfunction. J Contin Educ Urol 1979; 18:17.
86. , Oxybutynin: a new drug with analgesic and anticholinergic properties. J Urol 1972; 108:307–9.
87. , , Tolterodine – a new bladder selective muscarine receptor antagonist: preclinical pharmacological and clinical data. Life Sci 1997; 60:1129–36.
88. , , , Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor over activity and symptoms of frequency, urge incontinence and urgency: urodynamic evaluation. World J Urol 1997; 15:144–51.
89. , , , et al. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur Urol 2005; 47:376–84.
90. , , , , Extended-release trospium chloride improves quality of life in overactive bladder. Value Health. 2010; 13(2):251–7.
91. , , Which muscarinic receptor is important in the bladder? World J Urol 2001; 19:299–306.
92. , , , , Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis. Mult Scler 2010; 16:1349–59.
93. , Oxybutynin in bladder spasms, neurogenic bladder and enuresis. Urology 1976; 8:452–4.
94. , Oxybutynin chloride (Ditropan) clinical uses and applications. Paraplegia 1980; 18:64–8.
95. , , The urodynamic and subjective results of treatment of detrusor instability with oxybutynin chloride. Br J Urol 1980; 52:472–5.
96. , , , et al. Randomized, double-blind multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. J Urol 1991; 145:813–17.
97. , , , The treatment of detrusor instability in post menopausal women with oxybutynin hydrochloride, a double blind placebo controlled study. Br J Obstet Gynaecol 1990; 97:521–6.
98. , , , Treatment of lower urinary tract dysfunction in patients with multiple sclerosis. J Neurol 1992; 55:986–9.
99. , Control of detrusor hyperreflexia by the intravesical instillation of oxybutynin hydrochloride. Paraplegia 1991; 28:84–90.
100. , Intravesical oxybutynin in children with neurogenic bladder. J Urol 1991; 146:532–4.
101. Relaxation of intestinal bladders by intravesical oxybutynin chloride. Neurourol Urodyn 1990; 9:179–82.
102. , , Topical oxybutynin chloride for relaxation of dysfunctional bladders. J Urol 1989; 141:350–2.
103. , , Intravesical lidocaine and detrusor instability. Br J Urol 1979; 51:500–3.
104. , , Effects of instillation of verapamil into patients with detrusor hyperactivity. Neurourol Urodyn 1987; 6:253–6.
105. , , Intravesical oxybutynin: experience with 42 patients. Urology 1993; 41:527–30.
106. , , Sensory substance P-innervation of the urinary bladder: possible site of action of capsaicin in causing urinary retention in rats. Neuroscience 1983; 10:861–8.
107. , Resiniferatoxin and its analogs provide novel insights into the pharmacology of the vanilloid (capsaicin) receptor. Life Sci 1990; 47:1339–408.
108. , , , et al. Cystometric evidence that capsaicin sensitive nerves modulate the afferent branch of the micturition reflex in humans. J Urol 1989; 142:150–4.
109. , , , et al. Intravesical capsaicin as a treatment for refractory detrusor hyperreflexia: a dual center study with long term follow-up. J Urol 1997; 158:2087–92.
110. , , , et al. Intravesical capsaicin for the treatment of detrusor hyperreflexia. J Neurol Neurosurg Psychiatry 1994; 57:169–73.
111. , , , et al. Intravesical capsaicin for neurogenic bladder dysfunction. Lancet 1992; 339:1239.
112. , , Urodynamic effects of intravesical resiniferatoxin in humans: preliminary results in stable and unstable detrusor. J Urol 1997; 158:2093–6.
113. , , The use of desmopressin for nocturia in women with multiple sclerosis. J Neurol Neurosurg Psychiatry 1983; 46:854–5.
114. , Desmopressin: a new principle for symptomatic treatment of urgency and incontinence in patients with multiple sclerosis. Scand J Urol Nephrol 1990; 24:109–12.
115. , , , et al. An open in-patient incremental safety study of desmopressin in women with multiple sclerosis and nocturia. Br J Urol 1995; 76:459–63.
116. , , Desmopressin in the management of nocturia in patients with multiple sclerosis. Arch Neurol 1996; 53:1270–5.
117. , , , et al. Botulinum toxin type A is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 2005; 174:196–200.
118. , , , Botulinum toxin for the treatment of lower urinary tract symptoms: a review. Neurourol Urodyn 2005; 24:2–12.
119. , , , , , , The clinical and urodynamic results of a 3-month percutaneous posterior tibial nerve stimulation treatment in patients with multiple sclerosis-related neurogenic bladder dysfunction. Neurourol Urodyn. 2009; 28:964–8.
120. Alpha blockers and urethral pressure in neurological patients. Urol Int 1978; 33:304–9.
121. , , , et al. Do alpha blockers have a role in lower urinary tract dysfunction in multiple sclerosis? J Urol 1995; 153:1114–16.
122. , Efficient treatment of neurogenic bladder disorders in multiple sclerosis with intermittent catheterization and ultrasound controlled training. Eur J Neurol 1990; 30:260–7.
123. , , , , A randomized controlled trial: outcomes of bladder rehabilitation in persons with multiple sclerosis. J Neurol Neurosurg Psychiatry 2010; 81:1033–8.
124. , Urinary diversion and reconstruction in the patient with spinal cord injury Urol Clin North Am 1993; 20:465–74.
125. , , The use of electrical devices for the treatment of bladder dysfunction: a review of methods. J Urol 2004; 172:846–51.
126. , , , Incontinent ileo-vesicostomy urinary diversion in the treatment of lower urinary tract dysfunction. J Urol 1994; 152:99–102.
127. , , , Urolume urethral wall stent in the treatment of detrusor sphincter dyssynergia. Paraplegia 1994; 32:616–21.
128. , , , Wallstents in patients with detrusor sphincter dyssynergia. J Urol 1995; 154:495–7.
129. , , , Unusual therapeutic response of massive squamous cell carcinoma of the bladder. J Urol 1982; 128:1313–15.
130. , , Cancer of the bladder in spinal cord injury patients. J Urol 1981; 125:196–7.
131. , , Malignant vesical tumors following spinal cord injury. J Urol 1987; 138:1390–2.
132. , , , Continent ileocecal augmentation cystoplasty. Spinal Cord 1998; 36:246–51.
133. Electrical stimulation for the treatment of urinary incontinence. Urology 1998; 51(Suppl 2A):24–6.
134. , , , et al. Longterm results of a multicenter study on sacral nerve stimulation for treatment of urinary urge incontinence, urgency-frequency, and retention. Urology 2000; 56(Suppl 1):87–91.
135. , , Female stress incontinence due to intrinsic sphincter deficiency: recognition and management. J Urol 1996; 165:3–17.
136. , Periurethral injection of collagen in the treatment of intrinsic sphincteric deficiency in the female patient. Urol Clin North Am 1995; 22:673–8.
137. , Alteration in detrusor behavior and the effect on renal function following insertion of the artificial urinary sphincter. J Urol 1986; 136:632–5.
138. , , Sexual problems in patients suffering from multiple sclerosis. J Chron Dis 1976; 29:643–7.
139. Sexual impotence and some autonomic disturbances in men with multiple sclerosis. Acta Neurol Scand 1969; 45:166–82.
140. , , , Erectile dysfunction in multiple sclerosis. Associated neurologic deficits, and treatment of the condition. Brain 1994; 117:1303–10.
141. , , , et al. Erectile impotence in multiple sclerosis: a neurophysiological study. J Neurol 1995; 242:123–6.
142. , , , Multiple sclerosis. Sexual dysfunction and its response to medications. Arch Neurol 1995; 52:862–8.
143. , Sexual dysfunction in multiple sclerosis. Arch Phys Med Rehabil 1984; 65:125–8.
144. Sexual dysfunction in patients with multiple sclerosis. Sex Disabil 1978; 1:218–22.
145. , , Erectile dysfunction in multiple sclerosis. Neurology 1988; 38:1366–74.
146. , , , et al. Sexual dysfunction in multiple sclerosis: a case-control study. I. Frequency and comparison of groups. Mult Scler 1999; 5:418–27.
147. , , , et al. Sexual dysfunction in multiple sclerosis: a 2-year follow-up study. J Neurol Sci 2001; 187:1–5
148. , , , et al. Bladder and sexual function among women with multiple sclerosis. Mult Scler 2004; 10:455–61.
149. , Sexuality and multiple sclerosis. In , eds., Multiple Sclerosis and the Family. New York: Demos, 1992; 63–82.
150. , , , , Multiple sclerosis patients with and without sexual dysfunction: are there any differences? Mult Scler 2006; 12:209–14.
151. , , , et al. Correlation of sexual dysfunction and brain magnetic resonance imaging in multiple sclerosis. Mult Scler 2003; 9:108–10
152. , , , et al. Sexual dysfunction in multiple sclerosis: a MRI, neurophysiological and urodynamic study. J Neurol Sci 2003; 210:73–6.
153. , Yohimbine for erectile dysfunction: a new systematic review and meta-analysis of randomized clinical trials. J Urol 1998; 159:433–6.
154. , , , et al. Therapeutic effects of high dose yohimbine hydrochloride on organic erectile dysfunction. J Urol 1998; 159:122–4.
155. , , , et al. Clinical guidelines panel on erectile dysfunction: summary report on the treatment of organic erectile dysfunction. J Urol 1996; 156:2007–11.
156. , , , et al. Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double blind, placebo controlled pivotal trial. Urology 2003; 61(Suppl 1):8–14.
157. , , , et al. Vardenafil is effective and well-tolerated for treating erectile dysfunction in a broad population of men, irrespective of age. BJU Int 2005; 95:110–16.
158. , , , et al. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998; 338:1397–404.
159. , , , et al. Efficacy and treatment satisfaction with on-demand tadalafil (Cialis) in men with erectile dysfunction. Eur Urol 2004; 46:362–9.
160. , , , et al. A double blind randomized study of sildenafil citrate for erectile dysfunction in men with multiple sclerosis. J Neurol Neurosurg Psychiatry 2005; 76:700–5.
161. , , , et al. Sildenafil (Viagra): a double-blind, placebo-controlled, single-dose, two-way crossover study in men with erectile dysfunction caused by traumatic spinal cord injury [Abstract]. J Urol 1997; 157(Suppl):181.
162. , A once-daily dose of tadalafil for erectile dysfunction: compliance and efficacy. Drug Des Devel Ther 2010; 4:159–71.
163. , , Ejaculation induced by penile vibratory stimulation in men with spinal cord injuries. The importance of the vibratory amplitude. Paraplegia 1994; 32:651–60.
164. , , , An open trial of vacuum penile tumescence constriction therapy for neurological impotence. Paraplegia 1992; 30:550–3.
165. , , , et al. Use of intracavernous injection of prostaglandin E1 for neuropathic erectile dysfunction. Paraplegia 1994; 32:661–4.
166. , Long term follow-up of patients with erectile dysfunction commenced on self-injection with intracavernosal papaverine with or without phentolamine. Br J Urol 1996; 78:628–31.
167. , , , Brettschneider N. Reasons for high drop-out rate with self injection therapy for impotence. Int J Impot Res 1994; 6:171–4.
168. , Penile prosthesis for impotence in multiple sclerosis. Ann Neurol 1978; 5:451–4.
169. , , , et al. Safety and efficacy of Mentor alpha-1 inflatable penile prosthesis implantation for impotence treatment. J Urol 1997; 157:833–9.
170. , , , et al. Clinical experience with Mentor alpha 1 inflatable penile prosthesis. Urology 1993; 42:305–8.
171. , , Comparison of long term outcomes of penile prosthesis and intracavernosal injection therapy. J Urol 1998; 159:811–15.
172. , , , et al. Sexual disturbances arising from multiple sclerosis. Acta Neurol Scand 1984; 70:299–306.
173. , , A short form scale to measure sexual discord in dyadic relationships. J Sex Res 1981; 17:157–74.
174. , , et al. Sexual dysfunction in newly diagnosed multiple sclerosis women. Mult Scler 2008; 14:561–3.
175. Disturbances in micturition associated with disseminated sclerosis. Nerv Ment Disord 1938; 88:760–70.
176. , , , et al. Efficacy of sildenafil in the treatment of female sexual dysfunction due to multiple sclerosis. J Urol 2004; 171:1189–93.
177. , , , Sildenafil effects on sexual and cardiovascular response in women with spinal cord injury. Urology 2000; 55:812–15.